Variability in Anxiety and Depression Over Time Following Diagnosis in Patients with Prostate Cancer

Sharpley, Christopher F.; Christie, David; Bitsika, Vicki

doi:10.1080/07347332.2010.516810

Cited by 22 publications

(26 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Those data suggest that PCa patients exhibit different depressive profiles at different times following their diagnosis, arguing for variability in treatment protocols also. As reported in a previous study [39], the "one size fits all" treatment approach suffers in the face of changing depressive profiles during the three years after initial PCa diagnosis, and may need to be more closely aligned to the kinds of symptom variability shown in Figure 1. While Figure 1(a) can inform therapists about the 'danger' periods for Melancholia, Anhedonia and Agitation, Figure 1(b) may also provide some planning suggestions regarding the comparative attention to be given to the Anhedonia vs Agitation aspects of Melancholia in PCa patients.…”

Section: Discussionmentioning

confidence: 98%

The role of Melancholia in prostate cancer patients' depression

Sharpley

Bitsika

Christie³

2011

BMC Psychiatry

Self Cite

View full text Add to dashboard Cite

BackgroundAlthough it is well established that prostate cancer (PCa) patients are more likely to experience clinical depression than their age-matched non-prostate cancer peers, and that such depression can have negative effects upon survival, little is known about the underlying nature of the depressive symptomatology that these men experience. In particular, the incidence of melancholic symptoms of depression, which are signs of increased risk of suicide and resistance to treatment, has not previously been reported in PCa patients. The present study aimed to measure the incidence and nature of Melancholia in PCa depression.MethodA sample of 507 PCa patients in Queensland, Australia, completed anonymous and confidential questionnaires about their background, treatment status, and depression. Data were analysed to select depressive symptoms that were part of the definition of Melancholia vs those which were not. Regression was used to determine the links between Melancholia and overall depressive status, and factor analysis revealed the underlying components of Melancholia, which were mapped over time since diagnosis for 3 years.ResultsPsychometric data were satisfactory. Melancholia significantly predicted depressive status for the most depressed subset of patients, but not for the total sample. Melancholia was factored into its components of Anhedonia and Agitation, and the first of these was more powerful in predicting Melancholia. Variability over the 3 years following diagnosis was noted for each of these two components of Melancholia.ConclusionsThe strong presence of Melancholia in the depressive symptomatology of this sample of PCa patients suggests that some forms of treatment for depression may be more likely to succeed than others. The dominance of Anhedonia and Agitation over other symptoms of Melancholia also holds implications for treatment options when assisting these men to cope with their depression.

show abstract

Section: Discussionmentioning

confidence: 98%

The role of Melancholia in prostate cancer patients' depression

Sharpley

Bitsika

Christie³

2011

BMC Psychiatry

Self Cite

View full text Add to dashboard Cite

show abstract

“…Improved survival brings the problems of cancer survivorship into focus. In particular, between 15% and 26% of survivors experience clinically significant anxiety and depression 3 to 5 years following treatment …”

Section: Introductionmentioning

confidence: 99%

“…Thus, symptom occurrence and any effects of those symptoms on anxiety or depression will not be captured in research that measures predictors shortly after diagnosis or treatment. Posttreatment symptoms and functional problems predict anxiety and depression symptoms in cross‐sectional studies, but cross‐sectional designs cannot show causality. We are not aware of prospective research that tests whether posttreatment symptoms and functional problems are linked to long‐term anxiety and depression.…”

Section: Introductionmentioning

confidence: 99%

Predictors of anxiety and depression 2 years following treatment in uveal melanoma survivors

et al. 2018

View full text Add to dashboard Cite

show abstract

“…For example, in several previous studies, we have found that there are different relationships found between various factors of the combined SAS-SDS "anxiety-depression" construct and PCa (Sharpley et al, 2010b;Sharpley & Christie, 2007a). Those investigations with larger samples of PCa patients revealed four underlying factors in the SAS-SDS scores of this population, labeled as Fear and Sadness, Psychological Agitation and Pessimism, Fatigue, Pain and Discomfort, and Physiological Arousal (Sharpley, Christie, & Bitsika, 2010), and the association between reported hormonal side effects and these SAS-SDS factors was investigated here to further clarify the effects that these side effects had upon the PCa patients sampled who reported such side effects.…”

Section: Resultsmentioning

confidence: 85%

“…This group of symptoms from the SAS-SDS combination reflects the kinds of psychological disquiet and lack of confidence that PCa patients may have about the likely outcome of their treatment and of their future health (Sharpley et al, 2010). That is, apart from the unpleasantness of their treatment (e.g., AAT side effects), this factor represents the absence of a sense of focus and optimism that these patients might experience regarding their overall PCa treatment and their future lives.…”

Section: Discussionmentioning

confidence: 93%

Do Patient-Reported Androgen-Deprivation Therapy Side Effects Predict Anxiety and Depression Among Prostate Cancer Patients Undergoing Radiotherapy? Implications for Psychosocial Therapy Interventions

Sharpley¹,

Bitsika²,

Christie³

2012

Journal of Psychosocial Oncology

Self Cite

View full text Add to dashboard Cite

Antiandrogen therapy (AAT) is a common adjunct treatment for prostate cancer (PCa) patients and has shown significant benefits to long-term outcomes from radiation or surgery. Although AAT has some adverse side effects and data from breast cancer patients indicate that such side effects from hormonal therapies may contribute to anxiety and depression and may also hinder AAT treatment compliance, this issue has not been investigated within a sample of PCa patients. This study explores the incidence of AAT side effects in a sample of PCa patients, the links between those side effects and anxiety and depression, the possible ways in which these factors may contribute to AAT treatment noncompliance in PCa patients, and how psychosocial treatments might be developed to attend to this issue. 147 PCa patients completed questionnaires on demographic factors, treatment compliance, AAT side effects, anxiety and depression. About 18% of the sample reported AAT side effects, and there was a significant association between the presence of side effects and elevated anxiety and depression scores. Increased frequency of side effects was significantly associated with elevated anxiety, but not depression. The most powerful relationship between AAT side effects and anxiety-depression was for the subfactors of (1) Fatigue, Pain and Discomfort, and (2) Psychological Agitation and Pessimism. Although fatigue, pain, and discomfort may be outcomes of the hormonal treatment itself, psychological agitation and pessimism represent a discrete psychological pathway between AAT side effects and anxiety and depression and (potentially) treatment noncompliance. Methods of addressing patients' loss of optimism in their treatment outcomes are discussed.

show abstract

Variability in Anxiety and Depression Over Time Following Diagnosis in Patients with Prostate Cancer

Cited by 22 publications

References 31 publications

The role of Melancholia in prostate cancer patients' depression

The role of Melancholia in prostate cancer patients' depression

Predictors of anxiety and depression 2 years following treatment in uveal melanoma survivors

Do Patient-Reported Androgen-Deprivation Therapy Side Effects Predict Anxiety and Depression Among Prostate Cancer Patients Undergoing Radiotherapy? Implications for Psychosocial Therapy Interventions

Contact Info

Product

Resources

About